Bio-Rad Laboratories vs Revvity: revenue, profit, margins and growth compared
Bio-Rad Laboratories brought in $2.6B of revenue in fiscal 2025, Revvity $2.9B in fiscal 2025. Revenue changed by +0.7% at Bio-Rad Laboratories and +3.7% at Revvity on the year before, so Revvity grew faster. Bio-Rad Laboratories kept 29.4% of its revenue as net profit, Revvity 8.4%. Free cash flow was $374.6M at Bio-Rad Laboratories and $509.4M at Revvity.
Fiscal years as each company reports them; the two may end in different months.
Questions about Bio-Rad Laboratories and Revvity
Which is bigger by revenue, Bio-Rad Laboratories or Revvity?
Revvity is bigger by revenue: $2.9B in fiscal 2025, against $2.6B for Bio-Rad Laboratories in fiscal 2025.
Which keeps more of its revenue as profit, Bio-Rad Laboratories or Revvity?
Bio-Rad Laboratories had a net margin of 29.4% in fiscal 2025; Revvity had 8.4% in fiscal 2025.
Which grew revenue faster, Bio-Rad Laboratories or Revvity?
In their latest fiscal years revenue changed by +0.7% at Bio-Rad Laboratories and +3.7% at Revvity.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.